Solaropsis brasiliana, anatomy, range extension and its phylogenetic position within pleurodontidae (Mollusca, gastropoda, stylommatophora)

A detailed anatomical revision on Solaropsis brasiliana (Deshayes 1832) has been carried out. New characters on shell, anatomy of soft parts, and a review of the genus distribution in South America, as well as clarification on S. brasiliana distributional area are provided in the present study. Solaropsis brasiliana is diagnosed by its globose, solid, and hirsute shell, with periphery obsoletely angular, bursa copulatrix with a thick, long diverticulum, a thick, long flagellum and a penis retractor muscle forked, with the vas deferens passing through it. This compiled information was used to test the phylogenetic position of S. brasiliana within South American Pleurodontidae through a cladistics analysis. In the phylogenetic hypothesis obtained, S. brasiliana is sister group of S. gibboni (Pfeiffer 1846) and the monophyly of the genus Solaropsis Beck is also supported. Here, we sustain that the distribution of S. brasiliana is restricted to Brazil, inhabiting the States of Rio de Janeiro, Espírito Santo, Bahia and Minas Gerais.Fil: Cuezzo, Maria Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto de Biodiversidad Neotropical. Universidad Nacional de Tucumán. Facultad de Ciencias Naturales e Instituto Miguel Lillo. Instituto de Biodiversidad Neotropical. Instituto de Biodiversidad Neotropical; ArgentinaFil: De Lima, Augusto P.. Universidade do Estado de Rio do Janeiro; BrasilFil: Barbosa Santos, Sonia B.. Universidade do Estado de Rio do Janeiro; Brasi

Avaliação de indicadores sociais em agroecossistemas com barragens subterrâneas no semiárido Baiano, Brasil

O semiárido brasileiro vem passando por uma gama de mudanças sociais proporcionadas por políticas públicas que vem possibilitando o desenvolvimento de territórios em toda a região. Esse trabalho tem por objetivo avaliar esses agroecossistemas utilizando indicadores sociais. Na amostragem feita foram selecionadas três propriedades no Estado da Bahia: uma no município de Serrolândia e as outras duas no município de Canudos, todas localizadas em clima semiárido. O acesso à água possibilitou algumas transformações sociais positivas porque permitiu um aumento da capacidade produtiva no tempo e no espaço. Mas, quando relacionados ao direito a terra e a questões de direitos básicos como saúde e educação, observa-se que as tecnologias e inovações não têm interferido pouco no que se refere a acesso. O desenvolvimento dessas propriedades dentro dos princípios agroecológicos ainda está entre o nível baixo e intermediário, deixando claro que a sustentabilidade desses agroecossistemas depende do desenvolvimento de fatores sociais, econômicos e econômicos de forma integrada.The Brazilian semiarid region is going through a range of social changes caused by public policies that has enabled the development of territories across the region. This study aims to evaluate these agroecosystems using social indicators. In three properties sampled were selected in the state of Bahia, one in the municipality of Serrolândia and the other two in the municipality of Canudos, all located in semi-arid climate. Access to water has enabled some positive social change because it allowed an increase in production capacity in time and space. But when related to land rights and the basic rights issues such as health and education, it is observed that the technologies and innovations have not interfered little with regard to access. The development of these properties within the agro-ecological principles is still among the low and middle, making it clear that the sustainability of agro-ecosystems depends on the development of social, economic and economic factors in an integrated manner.Eje: A1 Sistemas de producción de base agroecológica (Trabajos científicos)Facultad de Ciencias Agrarias y Forestale

Avaliação de indicadores sociais em agroecossistemas com barragens subterrâneas no semiárido Baiano, Brasil

O semiárido brasileiro vem passando por uma gama de mudanças sociais proporcionadas por políticas públicas que vem possibilitando o desenvolvimento de territórios em toda a região. Esse trabalho tem por objetivo avaliar esses agroecossistemas utilizando indicadores sociais. Na amostragem feita foram selecionadas três propriedades no Estado da Bahia: uma no município de Serrolândia e as outras duas no município de Canudos, todas localizadas em clima semiárido. O acesso à água possibilitou algumas transformações sociais positivas porque permitiu um aumento da capacidade produtiva no tempo e no espaço. Mas, quando relacionados ao direito a terra e a questões de direitos básicos como saúde e educação, observa-se que as tecnologias e inovações não têm interferido pouco no que se refere a acesso. O desenvolvimento dessas propriedades dentro dos princípios agroecológicos ainda está entre o nível baixo e intermediário, deixando claro que a sustentabilidade desses agroecossistemas depende do desenvolvimento de fatores sociais, econômicos e econômicos de forma integrada.The Brazilian semiarid region is going through a range of social changes caused by public policies that has enabled the development of territories across the region. This study aims to evaluate these agroecosystems using social indicators. In three properties sampled were selected in the state of Bahia, one in the municipality of Serrolândia and the other two in the municipality of Canudos, all located in semi-arid climate. Access to water has enabled some positive social change because it allowed an increase in production capacity in time and space. But when related to land rights and the basic rights issues such as health and education, it is observed that the technologies and innovations have not interfered little with regard to access. The development of these properties within the agro-ecological principles is still among the low and middle, making it clear that the sustainability of agro-ecosystems depends on the development of social, economic and economic factors in an integrated manner.Eje: A1 Sistemas de producción de base agroecológica (Trabajos científicos)Facultad de Ciencias Agrarias y Forestale

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030